Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules

Nephrology Dialysis Transplantation

Volumn 11, Issue 1, 1996, Pages 125-132

  Barata, J D ^a   D'Haese, P C ^b   Pires, C ^c   Lamberts, L V ^b   Simoes J ^a   De Broe, M E ^b  

^a HOSPITAL DE SANTA CRUZ   (Portugal)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Hospital Distrital de Evora   (Portugal)

Author keywords

Acute; Administration schedule; Aluminium intoxication; Desferrioxamine; Treatment

Indexed keywords

ALUMINUM; CHELATING AGENT; DEFEROXAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIURESIS; FERRITIN BLOOD LEVEL; HALLUCINATION; HEADACHE; HEMODIALYSIS; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; MEAN CORPUSCULAR VOLUME; MYOCLONUS SEIZURE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; VISUAL IMPAIRMENT; WATER SUPPLY;

EID: 0030045385     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.1.125     Document Type: Article

References (44)

1. Alfrey AC, Mishell JM, Burks J et al. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972; 18: 257-261
2. Rosenbek JC, McNeill MR, Lemme ML, Prescott TE, Alfrey AC. Speech and language findings in a chronic hemodialysis patient. J Speech Hear Disord 1975; 40: 245-252
3. Pierides AM, Edwards WG, Cullum UX, McCall JT, Ellis HA. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980; 18. 115-124
4. Mahurkar SD, Meyers L, Cohen J, Kamath RV, Dunea G. Electroencephalographic and radionuclide studies in dialysis dementia. Kidney Int 1978; 13: 306-315
5. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med 1976; 294: 184-188
6. Flendrig JA, Kruis H, Das HA. Aluminium and dialysis dementia. Lancet 1976; 1: 1235
7. Ackrill, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from a patient with dialysis encephalopathy. Lancet 1980; 2: 692-693
8. Fuchs C, Armstrong VW, Quellhorst E, Scheler F. Prophylaxis and methods for early recognition of aluminium intoxication. Contrib Nephrol 1984; 38: 81-91
9. Pierides AM, Pierce Myli M. Therapy of aluminium overload (I). Contrib Nephrol 1984; 38: 65-67
10. Simon P, Allain P, Ang KS, Cam G, Mauras Y. Prevention and treatment of aluminium intoxication in chronic renal failure. Adv Nephrol 1984; 14: 439-478
11. Charhon SA, Chavassieux P, Boivin G et al. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study. Clin Sci 1987; 73: 227-234
12. Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F. Desferrioxamine therapy in hemodialysis patients with aluminium-associated bone disease. Kidney Int 1989; 35. 1371-1378
13. Ackrill P, Ralston AJ, Day P. Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int 1986; S-29: 104-107
14. Hood SA, Clark WF, Hodsman AB et al. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-α hydroxycholecalciferol. Am J Nephrol 1984; 4: 369-374
15. Thielemans C, Collart RW, Smeyers-Verbeeke, van Hooff I, Dratwa M, Verbeelen D. Improvement of anemia with deferoxamine in hemodialysis patients with aluminium-induced bone disease. Clin Nephrol 1985; 24: 237-241
16. Roger SD, Stewart JH, Harris DCH. Desferrioxamine enhances the haematopoietic response to erythropoietin, but adverse effects are common. Nephron 1991; 58: 33-36
17. D'Haese PC, Lamberts LV, Liang L, Boone LP, Van Waeleghem J-P, De Broe ME. Contribution of parenteral and dialysate solutions to the aluminium accumulation in dialysis patients. Blood Purif 1990; 8: 359-362 (Letter)
18. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminium accumulation during treatment with aluminium hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324: 527-531
19. D'Haese PC, Clement JP, Elseviers MM, Lamberts LV, Van de Vyver FL, De Broe ME. Value of serum aluminium monitoring in dialysis patients: a multicentre study. Nephrol Dial Transplant 1990; 5 (1): 45-53
20. De Broe ME, D'Haese PC, Couttenye MM, Van Landeghem GF, Lamberts LV. New Insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial Transplant 1993; [Suppl 1]: 47-50
21. McDermott JR, Smith AI, Ward MK, Parkinson IS, Kerr DNS. Brain aluminium concentration in dialysis encephalopathy. Lancet 1978; 1: 901-903
22. Dunea G, Mahurkar SD, Mamdami B, Smith EL. Role of aluminium in dialysis dementia. Ann Intern Med 1978; 88: 502-504
23. Leather HM, Lewin IG, Colder E, Braybrooke J, Cox RR. Effect of water deionisers on fracturing osteodystrophy and dialysis encephalopathy in Plymouth. Nephron 1981; 29: 80-84
24. Arieff AI. Aluminium in the pathogenesis of dialysis encephalopathy. Am J kidney Dis 1985; 6: 317-321
25. Simões JC, Barata JD, D'Haese PC, Lamberts LV, De Broe ME. Cela n'arrive qu'aux autres. Nephrol Dial Transplant 1994; 9: 67-68
26. De Broe ME, Drüeke TB, Ritz E. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. (Consensus conference.) Nephrol Dial Transplant 1993; [Suppl 1]: 1-4
27. Rosenlöf K, Fyhrquist F, Tenhunen R. Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet 1990; 335: 247-249
28. Gallant T, Boyden MH, Gallant LA, Carley H, Freedman MH. Serial studies of auditory neurotoxicity in patients receiving desferrioxamine therapy. Am J Med 1987; 83: 1085-1090
29. McCauley J, Sorkin I. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4: 110-114
30. Pengloan J, Dantal J, Rossazza C, Abazza M, Nivet H. Ocular toxicity after a single venous dose of desferrioxamine in 2 hemodialyzed patients. Nephron 1987; 6: 211-212
31. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In-vitro and in-vivo animal studies. J Clin Invest 1993; 91: 1979-1986
32. Verpooten GA, D'Haese PC, Boelaert JA, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose-finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1992; 7: 931-938
33. Vasilakakis DM, D'Haese PC, Lamberts LV, Lemoniatou E, Digenis PN,. De Broe ME. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis. Kidney Int 1992; 41: 1400-1407
34. D'Haese PC, De Broe ME. Aluminium toxicity. In: Daugirdas JT, Ing TS, eds. Handbook of Dialysis. Little, Brown, Boston, 1994; 522-536
35. D'Haese PC, Couttenye MM, Goodman WG et al. Value of the low-dose desferrioxamine test (5 mg/kg-10 mg/kg) in the diagnosis of aluminium-related bone disease aluminium overload. Nephrol Dial Transplant (1995); 10: 1874-1884
36. D'Haese PC, Van de Vyver FL, de Wolff FA, De Broe ME. Measurement of aluminium in serum, blood, urine, and tissues of chronic hemodialyzed patients by electrothermal atomic absorption spectrometry. Clin Chem 1985; 31: 24-29
37. Stragier A. Aluminium intoxication: are we protected at our unit. Nephrology News Issues/Europe 1994; 2: 5
38. Van Landeghem GF, D'Haese PC, Lamberts LV, Ammerlaan CC, van Eijk HG, De Broe ME. Binding of aluminium to transferrin is limited: comparison of various methodologies. Ann Clin Lab Sci 1995; 25: 459 (Abstract)
39. Van Landeghem GF, D'Haese PC, Lamberts LV, De Broe ME. Aluminium in cerebrospinal fluid is not bound to transferrin. Proc 8th International Congress of Nephrology, Madrid, 2-6 July 1995 (Abstract)
40. Douthat WG, Acuña Aguerre G, Fernández Martín JL, Mouzo R, Cannata Andia JB. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration. Nephrol Dial Transplant 1994; 9: 1431-1434
41. Bourdeau AM, Plachot J-J, Cournot-Witmer G, Pointillart A, Balsan S, Sachs C. Parathyroid response to aluminium in vitro. Ultrastructural changes and PTH release. Kidney Int 1987; 31: 15-24
42. Kontoghiorghes GJ, Chambers S, Hoffbrand AV. Comparative study of iron mobilization from haemosiderin, ferritin, and iron (III) precipitates by chelators. Biochem J 1987; 241: 87-92
43. Van Landeghem GF, D'Haese PC, Lamberts LV, De Broe ME. Study on the competition between transferrin (Tf), citrate (Cit) and DFO for Al/Fe binding in dialysis patients. Nephrol Dial Transplant 1994; 9: 1006 (Abstract)
44. Altmann P, Butter K, Plowman D et al. Residual renal function in hemodialysis patients may protect against hyperaluminemia. Kidney Int 1987; 32: 710-716